Eight members of the National Institutes of Health (NIH) expert COVID-19 Treatment Guidelines Panel disclosed recent financial relationships with Gilead, the drugmaker that is introducing an expensive Coronavirus competitor to Hydroxychloroquine, the inexpensive …
